Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Uncontrolled Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Activity of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis

Next Previous
Trial Profile

An Open-Label Uncontrolled Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Activity of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 23 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nipocalimab (Primary)
  • Indications Myasthenia gravis
  • Focus Adverse reactions; Pharmacokinetics; Registrational; Therapeutic Use
  • Acronyms Vibrance-MG
  • Sponsors Janssen Research & Development

Most Recent Events

  • 17 Feb 2026 Planned End Date changed from 26 Jun 2026 to 2 Jul 2029.
  • 02 Dec 2025 According to Johnson & Johnson media release, the European Commission has approved a Marketing Authorisation for IMAAVY(nipocalimab), as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG). supported by the data from Vivacity-MG3 and Vibrance-MG trials.
  • 29 Oct 2025 According to the Johnson and Johnson Media Release, long-term extension (LTE) data will present at the 2025 Myasthenia Gravis Foundation of America (MGFA) Scientific Session and the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top